Neuroimmunol NeuroinflammationNeuroimmunology and Neuroinflammation2349-6142OAE Publishing Inc.10.20517/2347-8659.2020.07ReviewAn association between mitochondria and microglia effector function: what do we think we know?HarryGaylia Jean1ChildersGabrielle12GiridharanSahana13HernandesIrisyunuel Lopez11National Toxicology Program Laboratory, National Institute of Environmental Health Sciences, Durham, NC 27709, USA.2(Current affiliation) Gabrielle Childers, University of Albama at Birmingham, Birmingham, AL 35294, USA.3Sahana Giridharan, Duke University, Durham, NC 27708, USA.Correspondence Address: Gaylia Jean Harry, National Institute of Environmental Health Sciences, P.O. Box 12233, MD E1-07, Durham, NC 27709, USA. E-mail: harry@nih.gov
Received: 14 Jan 2020 | First Decision: 24 Feb 2020 | Revised: 7 Apr 2020 | Accepted: 7 Apr 2020 | Available online: 16 Jun 2020
While resident innate immune cells of the central nervous system, the microglia, represent a cell population unique in origin, microenvironment, and longevity, they assume many properties displayed by peripheral macrophages. One prominent shared property is the ability to undergo a metabolic switch towards glycolysis and away from oxidative phosphorylation (OXPHOS) upon activation by the pro-inflammatory stimuli lipopolysaccharide. This shift serves to meet specific cellular demands and allows for cell survival, similar to the Warburg effect demonstrated in cancer cells. In contrast, normal surveillance phenotype or stimulation to a non-proinflammatory phenotype relies primarily on OXPHOS and fatty acid oxidation. Thus, mitochondria appear to function as a pivotal signaling platform linking energy metabolism and macrophage polarization upon activation. These unique shifts in cell bioenergetics in response to different stimuli are essential for proper effector responses at sites of infection, inflammation, or injury. Here, we present a summary of recent developments as to how these dynamics characterized in peripheral macrophages are displayed in microglia. The new insights provided by an increased understanding of metabolic reprogramming in macrophages may allow for translation to the central nervous system and a better understanding of microglia heterogeneity, regulation, and function.
The function of innate immune cells such as macrophages is to recognize and respond to a novel stimulus including microbial pathogens and sterile activators. These pro- and anti-inflammatory responses are major sources of soluble molecules, cytokines, hormones, and neuropeptides These factors provide tools to sense, process, and relay physiological signals beyond their canonical roles. Macrophages display a heterogeneous repertoire to fulfill a broad range of functions in host defense, including tissue homeostasis and repair, pathology, and development. To accomplish this, innate immune cells adopt various activation phenotypes. Precise regulation of such activation is essential for maintenance of tissue homeostasis with governance accomplished by a balance of stimulatory and inhibitory signals. Multiple lines of evidence suggest an interlinked relationship between innate immunity and the integrity and function of mitochondria serving to maintain this homeostatic balance. Metabolic pathways provide the necessary energy and serve to regulate phenotype and function. Pro-inflammatory macrophages {M[LPS(+IFNγ)]} display an enhanced glycolytic metabolism and impaired mitochondrial oxidative phosphorylation (OXPHOS). These energy shifts place mitochondria in a pivotal signaling role in macrophage response to stimuli and circumventing immune checkpoint signals[1-3]. The link between immunological and metabolic processes associated with mitochondria, immunometabolism, may influence activation states and polarization of myeloid cells to fine-tune their functions[4-7].
Of the specialized cells of the central nervous system (CNS), basic host defense mechanisms exist predominantly in microglia as resident macrophages. Microglia share many phenotypic characteristics with peripheral macrophages yet are unique in their origin and molecular or transcriptional profile[8-15]. The available literature on the immunometabolism of microglia, as compared to what is known of peripheral macrophages, is limited but growing to address questions of similarities and differences[6,16]. It may also allow for a framework to understand the various other tasks undertaken by microglia during development and chronic maintenance. Here, we present a summary of how these dynamics characterized in peripheral macrophages are displayed in microglia. While much of this work is still somewhat under a “work in progress” classification, even in the peripheral macrophage, new insights provided by an increased understanding of metabolic reprogramming foster a better understanding of macrophage and microglia regulation and function.
Microglia and immune cells in the CNS
The mechanical separation of the CNS from the circulation by the blood-brain barrier[17,18] influences immune responses[19,20] by excluding many peripherally derived innate and adaptive immune cells and inflammatory molecules[21]. However, infiltrating cells significantly contribute to any neuroinflammatory response following disruption of the blood-brain barrier, as can occur with physical injury or high levels of inflammation. In such cases, blood-borne monocytes are allowed to enter the brain parenchyma and, over time, can transition and assume a brain-specific phenotype[22-24]. Additionally, with a T cell-mediated neuroinflammation, peripheral innate immune cells enter the brain as a protective host defense against infection and facilitate repair following stroke or physical trauma[25,26]. In such a case, interactions between microglia and T cells can be signaled via interleukin (IL)-23 and IL-1β, leading to the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) to facilitate microglia proliferation in a manner to promote an appropriate level of response to injury[27]. Recently, the identification of innate lymphoid cells in the brain suggests an additional innate immune cell population that may act to control neuroinflammation[28]. Thus, in such conditions, the macrophage population likely represents a combination of resident microglia and infiltrating monocytes. As a distinction between these two populations, it has been suggested that resident microglia focus on tasks related to maintaining tissue homeostasis while infiltrating cells are involved in severe inflammatory injuries[29,30].
Sensing and responding to the environment
While microglia appear to be tightly adapted to the specific requirements within brain regions, they all function in a surveillance mode with mobile processes extending into the surrounding microenvironment to detect tissue changes[31,32]. Upon sensing such changes, microglia respond to their environment via several “sensome” genes, allowing them to sense and interact with their local environment[8,14,33]. These sensome genes include those for putative purinergic receptors, P2ry12 and P2ry13, transmembrane protein 119 (Tmem119), G-protein coupled receptor 34 (Gpr34), the C-type lectin receptor, the fractalkine receptor, Cx3cr1, sialic acid-binding immunoglobulin-type lectin H (Siglec-h), and triggering receptor expressed on myeloid cells 2 (Trem2). Siglec proteins contribute to immune regulation by binding sialic acid residues on neurons[34] and TREM2 contributes via recruitment of the immunoreceptor tyrosine-based activation motif-containing adapter protein, DAP-12[35]. The final response of the cell is dictated by the overall pattern of sensome gene activation.
The microglia host-response begins with the recognition of pathogen-associated molecular patterns (PAMPs) such as bacterial, viral, and protozoal products (protein lipid, nucleic acid, and carbohydrate). This occurs via pattern recognition receptors on the plasma membrane or in the endosomal compartments[36], or by binding phagocytic scavenger receptors[37] and macrophage antigen complex I (MAC1, CD11b/CD18), which is a pattern recognition receptor linked to the superoxide-generating enzyme NADPH oxidase[38]. In the absence of microorganisms, a similar but sterile inflammatory response occurs often as a result of trauma, ischemia-reperfusion injury, or chemical exposure[39-41]. Activation in the absence of microbial compounds occurs by endogenous molecules called danger-associated molecular patterns (DAMPs)[42]. Molecules that function as DAMPs include nucleic acids, lipids, and proteins that normally are not present to immune cells until released or unmasked during cell death due to tissue injury. In the CNS, microglia responding in various neurodegenerative diseases in the absence of pathogen have been termed disease-associated microglia (DAM). Intracellular DAMPs include high mobility group box 1 (HMGB1) and peroxiredoxin family proteins. These damage signals can activate immune cells through three major families of intracellular recognition receptors: toll-like receptors, nucleotide-binding domain leucine-rich repeat containing proteins (also known as NOD-like receptors), and Rig1-like receptors. Receptor activation induces specific pathways and the release of cytokines that contribute to injury mitigation[43]. Microglia are influenced by a plethora of factors including receptor agonists[44-48] and transcription factor inducers[49]. It is thought that microglial receptors[50-52] can act as molecular switches to control microglial responses and that many of these actions function through alterations in calcium signals[53]. In all cases, the immediate response upon sensing DAMPs, PAMPs, or other damaging events requires a robust increase in metabolic demand to support actions that initially are beneficial to the homeostatic balance of the nervous system.
Injury-induced inflammatory processes are dynamic and demonstrate spatial and temporal heterogeneity[54-56]. In general, characterization of the macrophage response is based on the nature of the activating stimulus and the resulting production of factors[57]. A conceptual framework has been proposed that suggests the nature of the activating stimulus can drive a range of activation phenotypes[58-62], and it has been used as a basis for characterizing cellular responses[63-70]. While phenotypic activation-state distinctions are currently under scrutiny[67,71], it has been shown that classically activated microglia associated with inflammation can be produced upon stimulation with agonists for toll-like receptors (e.g., lipopolysaccharide, LPS) or IFNγ receptors. In contrast, different aspects of the immune response that do not involve the classical response can be observed upon stimulation by IL-4 or IL-13 with the expression of anti-inflammatory cytokines (IL-4, IL-10, IL-13, and TGF-β), arginase-1 (Arg1), CD206, and Chitinase-3-like-3 (Ym1 in rodents)[72-76]. It is considered that the different phenotypes may be related, yet have different roles in host defense, wound healing, and resolution of inflammation[57,60]. Differences in metabolic processes have been identified across these different activation inducers, suggesting a role for mitochondria in phenotypic outcome[77].
Stimulus-driven metabolic re-programming of microglia
In a normal “resting” cell, energy demands are addressed with the conversion of glucose to pyruvate with entry into glycolysis. Pyruvate in the cytosol can be taken up by mitochondria and enters the tricarboxylic acid (TCA) cycle where it is oxidized to generate ATP. This provides a total energy gain of approximately 36 ATP per one molecule of glucose. In contrast, with hypoxia or anoxia, the cell has the ability to divert pyruvate away from mitochondria OXPHOS, allowing for ATP generation during low oxygen conditions. In this case, one glucose molecule will generate two pyruvate molecules that will be converted to lactate by lactate dehydrogenase in the cytosol[78,79]. While this reaction generates significantly fewer molecules of ATP, glycolysis proceeds due to the production of NAD+. While less efficient, a beneficial effect of a shift to glycolysis is that it can be very quickly induced to meet cellular demands in cells with high glucose capacity[80]. The importance of this shift was initially demonstrated in cancer cells in what is known as the Warburg effect[81,82]. In cancer, malignant cells shift their demand for biosynthetic precursors and energy change and change their metabolic profile from a relatively low rate of glycolysis and the oxidation of pyruvate by the TCA cycle. The shift in metabolic profile is characterized by a lower rate of OXPHOS, high rate of glycolysis, and elevated lactic acid production. The high glycolytic rate induced during the Warburg effect is driven by the need to meet the increased demand for production of nucleotides and amino acids. While this effect was initially identified and characterized in cancer cells, a similar ability to utilize such a metabolic switch has been demonstrated in immune cells to meet increased energy demands when responding to infection or injury[1].
There is now evidence suggesting a role for metabolic reprogramming by mitochondria in the maintenance and establishment of innate and adaptive immune responses[75,83-96]. Given that immune cell populations depend on unique effector functions in response to distinct stimuli that often require production and secretion of high amounts of signaling factors and antimicrobial agents, it follows that changes in mitochondria function to meet these demands are crucial for efficient response to distinct contexts[97-101]. It was initially observed that, upon activation, macrophages increase glycolysis and decrease oxygen consumption[102,103]. It was further demonstrated that macrophage phenotype can be shifted by reprogramming glucose metabolism[104,105], which helps meet energy demands required for shifting cell function and survival[106].
Under normal conditions, microglia exist in a surveillance phenotype for constant monitoring of the parenchyma[107,108] and preferentially rely on oxidative metabolism[90,109,110]. Upon activation by LPS[94], amyloid-b[111], and iron loading[112,113], microglia switch their reliance on OXPHOS metabolism[69,110,114,115] towards glycolytic metabolism to maintain mitochondrial function and ensure cell survival[91,94,95,116]. Voloboueva et al.[94] showed that, upon stimulation by LPS, BV-2 microglia increased lactate production and decreased mitochondria oxygen consumption and ATP production. This shift was reported to be modulated by mitochondrial glucose-regulated protein 75/mortalin[94]. Exposure to a combination of LPS and IFN-γ increases nitric oxide formation, glucose consumption, hexokinase activity, glucose-6-phosphate dehydrogenase activity, phosphofructokinase-1 activity, lactate dehydrogenase activity, and lactate release, suggesting potentiated glycolysis[94]. Similar findings were reported by Orihuela et al.[69]: following LPS, BV2 microglia and primary murine microglia shifted from a primary oxidative metabolic towards glycolytic metabolism with no evidence of cell death. An increase in microglial mitochondria has been observed with activation[117,118], implicating an association with mitochondria biogenesis. Recent studies have suggested that a shift in glycolysis in microglia is accompanied by an increase in the enzyme PFKFB3, which is responsible for activation of phosphofructokinase[119]. Additionally, this metabolic shift has been found to be regulated by the anti-inflammatory cytokine IL-10 for aerobic glycolysis inhibition and OXPHOS[120].
In a non-classical activation state, macrophages use oxidative metabolism for functions involved in normal maintenance functions, tissue repair, and wound healing[73,121,122]. In IL-4 stimulated macrophages [M(IL-4)], the Krebs cycle and OXPHOS remain intact. In addition, the cells are able to utilize fatty acid oxidation and oxidative respiration for energy production[98,123-125] and arginine metabolism is shifted to ornithine and polyamines[126]. Work by Ferger et al.[118] suggested that the stability of the electron transport chain in mitochondria plays a more substantial and critical role for the microglia response to IL-4 as compared to the response to LPS. In microglia, exposure to LPS induced a rapid and transitory decrease in the mitochondrial uncoupling protein-2 (UCP-2) levels accompanied by increased mitochondrial reactive oxygen species (mtROS) production. In UCP-2-silenced microglia, the response to LPS was exacerbated and a response to IL-4 was eliminated[127]. An earlier study examining the translation of responses in macrophages to microglia reported reduced glucose consumption and lactate production in BV-2 cells exposed to IL-4[109]. It was suggested that this phenotype was associated with phagocytosis of debris and the reduced need for anabolic reactions. Similar findings were reported by Orihuela et al.[69] with exposure of BV-2 cells or primary murine microglia to IL-4/IL-13 in that the cells remained within an oxidative metabolic state with OCR and ECAR levels similar to non-stimulated cells. There were also elevations in mRNA levels for Ym1, Il4, Cd163, and Arg1, but no induction of Tnfa or Il1[69]. The lack of a demonstrated metabolic shift with IL-4/IL-13 stimulation is in contrast to observations in peripheral macrophages of stimulated glucose uptake in addition to fatty acid metabolism and shift in mitochondrial biogenesis[125].
Mitochondria and free radical production
A key feature of classically activated macrophages is their ability to produce reactive oxygen species (ROS) to facilitate killing of phagocytized bacteria[128]. Stimulation of macrophages with LPS and IFN-γ increases inducible nitric oxide synthase (iNOS), generating nitric oxide (NO), a reactive nitrogen species that can inhibit mitochondrial respiration by nitrosylating iron-sulfur proteins in electron transport chain complexes and cytochrome c oxidase[129,130]. It is considered that iNOS and NO-mediated inhibition of mitochondrial metabolism in macrophages is essential for the metabolic switch activated by LPS. This is not as well established in microglia, especially given that, while nitric oxide production is often linked with pro-inflammatory cytokines, such cytokines can be stimulated by sterile activators in the absence of NO. In microglia, it has been proposed that activation of the rapamycin (mTOR) pathway may actively contribute to this process[131] as well as pro-inflammatory cytokine production and phagocytic activity[132-134]. The resulting elevated thiamin pyrophosphate activity increased production of purines and pyrimidines, which yield nicotinamide adenine dinucleotide phosphate (NADPH) for the NADPH oxidase enzyme and ROS production[135] implicated in the transition of microglia to a pro-inflammatory phenotype[136-139]. It has been proposed that glycolytic ATP production may utilize the electron transport chain to compensate for this shift towards ROS production[128]. It is known that superoxide produced by NADPH oxidase is predominantly extracellular. In vivo, extracellular superoxide dismutase 3 (SOD3) forms membrane permeable H2O2. Studies have suggested that H2O2, rather than SOD, serves as the primary ROS involved in mediating microglial activation and proliferation in response to pro-inflammatory stimuli[136,140,141]. H2O2 has also been implicated in the increase in CD11b expression both in vitro and in vivo[142], as well as in persistent neuroinflammation related to impaired NF-kB p50 function[143]. Superoxide anion is the primary ROS produced by mitochondria and mitochondria-derived H2O2 and, in addition to NADPH oxidase, may contribute to a pro-inflammatory phenotype of microglia such as that observed with the mitochondrial toxin, rotenone[144]. With a response sufficient to result in ROS production, the associated intracellular damage is limited by increased generation of NADPH required for maintenance of reduced glutathione and nitric oxide production[145,146].
Glucose
In addition to the critical role that glucose plays in energy metabolism, it serves as an exclusive substrate for the hexose monophosphate shunt, which produces NADPH that is required by glutathione reductase to convert oxidized glutathione (GSSG) back to reduced glutathione (GSH). It also serves to quench ROS and repair oxidative damage through glutathione- and thioredoxin-coupled pathways[147]. Glucose metabolism influences microglial activation through an NADH-sensitive co-repressor termed C-terminal binding protein (CtBP). Slowed glucose flux through glycolysis reduces NADH levels and reduce NADH:NAD+ ratio[148]. In both microglia and macrophage RAW264.7 cells, glucose flux regulates iNOS expression and other pro-inflammatory genes through effects on cytosolic NADH:NAD+ ratio and CtBP[149].
Several glucose transporters such as GLUT1[150], GLUT3[151], and GLUT5[152] are expressed in microglia. Acute fluctuation of available glucose impacts microglia activity with an elevated response to LPS upon shifting from a normal to high glucose level. Shifting from a high to normal glucose level can also induce metabolic stress[153]. Glucose levels can influence pro-inflammatory gene transcription by several mechanisms. One such mechanism relies on the formation of advanced glycation end-products (AGE). These products consist of modified proteins and lipids as a result of non-enzymatic reactions with sugars. It is known that microglia express receptors of AGE and, upon activation, pro-inflammatory signaling pathways are stimulated[127,154]. In peripheral macrophages, it has been reported that a shift in the cell’s energy source induced by glucose deprivation results in an altered response to a pro-inflammatory stimulus[155-157]. Multiple studies have reported an inability of microglia to respond appropriately to LPS under oxygen and glucose deprivation or with 2-DG inhibition of glucose metabolism[109]. However, there is evidence that microglia are capable of functioning with alternative energy sources to adequately respond to an inflammatory challenge. Choi et al.[158] reported an increase in mRNA and protein levels for IL-6 in microglia after 7 h of glucose and serum free medium. Upon stimulation with LPS, glucose-deprived microglia retained their normal ability to respond with elevations in nitrite, IL-1β, and TNFα[159]. Primary rat microglia shifted to glucose-free medium for 1 h to LPS showed an exacerbated release of NO within 24 h and similar elevations in TNFα and IL-1β as compared to non-glucose-deprived cells. Glucose deprivation for 24 h prior to LPS exposure increased release of IL-1β with no deficits in NO or TNFα. The authors suggested that microglia were able to mobilize fatty acids from intracellular lipid droplets as an energy source. The majority of studies examining the effects of glucose deprivation have focused on relatively short-term exposures, within 1-24 h. While these studies demonstrated that both peripheral macrophages and microglia can shift their response to a pro-inflammatory stimulus in a selective manner, the question remains as to whether such a response would be altered when the cells were forced to a more prolonged shift in energy metabolism. When RAW 264.7 [Figure 1] or BV-2 [Figure 2] cells were maintained for three days under culture conditions to force cells to rely on galactose as an alternative energy source, the cells were able to normally respond to LPS stimulation. However, the diminished pro-inflammatory cytokine response observed when 2-DG was used in previous studies to inhibit glycolysis may have been related to the lower basal OXPHOS induced[160]. The differences across these studies likely lie with the method of depleting glucose: removing glucose from the medium; the addition of 2-DG, which in and of itself can lower basal induction of OXPHOS[160]; or the combination of glucose deprivation with hypoxia. In RAW cells, the morphological changes observed with LPS activation have been demonstrated to be diminished under galactose, suggesting a requirement of glucose to facilitate cell spreading[161]. This was not clearly observed in the current study where similar LPS-induced morphological patterns were observed in the absence of pyruvate [Figure 1]. In BV-2 cells, a slight morphological shift was observed with the low level of LPS stimulation with minimal induction of nitrate and an elevation in TNFα and IL-1 protein.
Response of RAW 264.7 cells to LPS under glucose or galactose medium conditions. RAW 264.7 cells were plated in 6-well tissue culture plates (Corning, Corning, NY) and maintained in normal growth medium (NM) [DMEM (Gibco, ThermoFisher, Waltham, MA) containing 4.5 g/L glucose, 2 mM L-glutamine, sodium pyruvate, supplemented with 100 U/mL penicllin/ streptomycin (Sigma-Aldrich, Burlington, MA) and 10% fetal bovine serum (FBS #1 00-106, 0.25 endotoxin units/mL; Gemini Bio-Products, Sacramento, CA) and allowed to reach 85% confluence over 3-5 days. Cells were maintained at 37 °C, 5% CO2/5% O2, 90% humidity (Nu-5831 tri-gas incubator, Nuaire, Plymouth, MN). NM was changed to phenol-free NM medium or phenol-free DMEM medium containing 2 mM L-glutamine and 100 U/mL penicillin/streptomycin supplemented with (2) high glucose (25 mM; Glu), or 3] galactose (10 mM; Gla). Cells were maintained in the experimental medium for 3 days following which, under the same media conditions, cells were exposed to lipopolysaccharide (LPS; 1 μg/mL; Sigma) for up to 18 h and monitored using a live cell imaging system (IncuCyte, Sartorius) under normal incubator conditions. (A) Representative images (20x) of cell morphology under normal medium (NM), high glucose (Glu), or galactose (Gla). Scale bar = 25 microns. (B) Samples were collected at 3 h post-LPS and mRNA isolated using TRIzol® Reagent (Invitrogen, Carlsbad, CA), and 2.5 μL cDNA was used for qRT-PCR for Tnfa, II 1a, II 1b, and cyclophilin A using TaqManTM. Individual gene expression levels were normalized to cyclophilin A and presented as fold-change from vehicle controls in each medium condition. Data were analyzed by 2-way ANOVA followed by Dunnett’s test for independent group mean comparisons. Data represent mean +/- SEM (n = 3-4). *Significance level as compared to vehicle control set at P < 0.05
Response of BV-2 cells to LPS under glucose or galactose medium conditions. BV-2 murine microglia cells were plated in 6-well tissue culture plates (Corning, Corning, NY) and maintained in normal growth medium (DMEM (Gibco, ThermoFisher, Waltham, MA) containing 4.5 g/L glucose, 2mM L-glutamine, supplemented with 100 U/mL penicillin/streptomycin (Sigma- Aldrich, Burlington, MA) and 10% fetal bovine serum (FBS #100-106, 0.25 endotoxin units/mL; Gemini Bio-Products, Sacramento, CA) and allowed to reach 85% confluence over 3-5 days. Cells were maintained at 37 °C, 5% CO2/5% O2, 90% humidity (Nu-5831 tri gas incubator, Nuaire, Plymouth, MN). The normal growth medium was changed to phenol-free complemented DMEM medium containing 2mM L-glutamine, supplemented with 100 U/mL penicllin/ strepto supplemented with 1) high glucose (25 mM), 2) low glucose (10 mM), 3) galactose (10mM), or 4) high glucose + galactose). Cells were maintained in the experimental medium for 3 days following which, under the same media conditions, cells were exposed to lipopolysaccharide (LPS; 100 ng/mL; Sigma) monitorec using a live cell imaging system (IncuCyte) under normal incubator conditions for up to 18 h. A: Representative images (20x) of cell morphology under high glucose (Hi Glu), low glucose (Lo Glu), or galactose (Gal). Scale bar = 200 microns; B: Nitrite accumulation in culture medium was measured as an indirect indicator of nitric oxide synthesis using a Greiss Reagent kit (Promega, Madison, WI) following manufacturer s instructions. Estimates were determined relative to standard curve; C: Estimates of the release of IL-1 into the medium were obtained using HEX BlueTM IL-1R cells (InvivoGen, San Diego, CA) following manufacturer’s instructions. From 20 μL aliquot of the medium, after a 1.5 h incubation at 37 °C, absorbance at 620 nm was measured using a BioTeck Synergy 4 plate reader. Data were calculated relative to background control; D: TNFα protein levels were determined by Mouse TNFα ELISA MAX kit (BioL egend, San Diego, CA) with BD OptEIA Reagent Set B according to manufacturer’ instructions. Absorbance was measured at 450nm with a 570nm background subtraction. Protein levels were determined based on standard curve and calculated relative to total cell number as determined using IncuCyte software. Data represent mean +/- SEM (n = 5-6). Data were analyzed by 2-way ANOVA followed by Bonferroni post-hoc comparisons. *Significance level as compared to vehicle control set at P < 0.05
Glutamine
Macrophages utilize glutamine at high rates to synthesize amino acids, nucleotides, NADPH, and energy production and are dependent upon extracellular sources of the amino acid[103]. Channeling of glutamine into the Krebs cycle is a primary route to promote succinate synthesis in macrophages. This occurs with glutamine being used for synthesis of glutamate, GABA, and succinate, bypassing the TCA cycle[155]. This stabilizes hypoxia-inducible factor 1-alpha (HIF-1α), an oxygen-sensitive transcription factor that allows the cell to adapt to a hypoxic environment[162]. It has been suggested that HIFs function to facilitate cross-talk between inflammation and metabolism[163]. HIF-1a can induce the expression of pro-inflammatory cytokines and has been proposed to serve a role in shifting glycolytic pathways to favor anaerobic metabolism[114]. With classic activation, succinate regulates HIF-1a to drive a sustained production of IL-1β[100] and the subsequent cell actions serve to maintain the macrophage survival. For the non-classical phenotype, glutamine metabolism acts at multiple levels including the generation of a-ketoglutarate and serves as a substrate for UDP-GlcNAc synthesis[164].
NLRP3 inflammasome
One biological response to an inflammatory event that is critically dependent upon metabolic regulation is inflammasome activation. This is especially relevant for inflammasomes that require prior cell priming for full activation upon a secondary stimulus. For example, glycolytic rate can influence formation of NLRP1 and NLRP3 inflammasomes in macrophages[165,166]. Inflammasomes are multiprotein complexes formed in the cytosol of immune and neural cells in response to pathogenic and danger signals. They consist of a cytosolic sensor belonging to the AIM2 (absent in melanoma 2), or NLR, an adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), and an effector caspase, primarily caspase-1. There are a variety of inflammasomes, most of which fall into the NLR domain[167]. NLRP1 and AIM2 inflammasomes have been characterized in neurons[168-170] and the NLRC4, NLRP2, and NLRP3 inflammasomes in astrocytes[171,172]. Components for multiple inflammasomes are expressed in microglia[173,174]. The NLRP3 inflammasome responds to a number of activators, including sterile activators, such as asbestos, silica crystals, aluminum salts, and polystyrene nanoparticles[175-178], and aberrant proteins, such as extracellular Aβ[179], thereby contributing to a broad range of common inflammatory pathologies and chronic inflammation.
The NLRP3 inflammasome responds to metabolic regulation[180] and has been increasingly recognized as a bridge between mitochondrial damage sensing and pro-inflammatory signaling within monocytes, including microglia[181,182]. Unlike most inflammasomes, NLRP3 typically requires a two-step activation and it is this process for which there is mounting evidence that mitochondrial damage plays a contributing role[101]. Activation of TLR, tumor necrosis factor receptor, or interleukin-1 receptor (IL-1R) initiates an intracellular cascade of effects, including activation of NF-kB. This upregulates NLRP3 and pro-IL-1β within the cell and facilitates post-transcriptional changes to NLRP3 to free ubiquitinated binding sites by BRCC3 (BRCA1/2-containing complex subunit 3)[176,183,184]. Delivery of a secondary “trigger” such as PAMPs, DAMPs, or intact pathogens to the “primed” cell causes the release of the repressed state of NLRP3. Upon release, NLRP3 activates the inflammasome forming a multiprotein complex comprised of the cytosolic sensor NLRP3, ASC, and caspase 1[185]. Caspase 1 facilitates the cleavage of the pro-forms of IL-1β and IL-18[186], resulting in the release of mature protein[187]. The release of active IL-1 family cytokines is normally related to pyroptotic cell death; however, in the absence of cell death, hyperactivity of cells and the recruitment of a process dependent on plasma membrane-localized pores can result in similar protein release[188,189]. While inflammasome activation is an efficient producer of mature IL-1β, inflammasome independent mechanisms exist, including cathepsin B or caspase 11 dependent pathways[190,191], bacterial pore-forming toxins, and extracellular ATP[177]. Thus, an upregulation of mature IL-1β does not automatically indicate an inflammasome mechanism. In addition to the release of inflammatory factors, the physical release of ASC specks into the extracellular environment represents a stimulus for activating phagocytic cells in the immediate environment, thus contributing to a prolonged propagation of inflammation[192] or other biological responses[193].
Induction of mitophagy, the process by which cells clear damaged mitochondria, has been implicated in inhibition of NLRP3 signaling[194]. Release of oxidized mitochondrial DNA (mtDNA) produced during the priming stage[195,196] can interact with the NLRP3 receptor and induce inflammasome activation. Nakahira et al.[196] reported that inhibition of mitophagy in macrophages heightened the NLRP3 inflammasome activation in parallel with uncleared mitochondrial DNA released into the cytosol. The mitochondrial cytidine/uridine monophosphate kinase-2 (CMPK2) is a nucleotide kinase required for mtDNA synthesis and production of oxidized mtDNA fragments. These fragments can act as activating ligands for the NLRP3 inflammasome complex[197]. In addition, the release of mtROS triggered by small molecule inhibition of complex I and III has been associated with NLRP3 inflammasome activation[198]. The association between mtROS as a trigger for NLRP3 inflammasome activation remains controversial given potential off-target effects of mtROS inhibitors. While studies have reported a role for mtROS in NLRP3 inflammasome activation, other conflicting studies have been reported. At least one study reported that mtROS inhibitors do not block the secondary activation step, but rather the initial priming step[199]. Apart from acting as an activator of NLRP3, mitochondria can act as a docking system for inflammasome assembly. This interaction is driven by the externalization of mitochondrial lipid cardiolipin from the inner membrane to the outer membrane, which then independently interacts with caspase-1 and NLRP3[200].
NLRP3 inflammasome activation in microglia has gained attention as a contributing mechanism in several neuroinflammatory disease pathologies including Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease[201-205]. While much is similar between the biochemistries of microglia and macrophages, differences in inflammasome activation have been reported. For example, exposure of microglia cells to the antioxidant NAC did not affect LPS priming yet inhibited Aβ 1-42 peptide stimulation of caspase-1 dependent IL-1β secretion[202]. While microglia show similar expression of inflammasome components and response to stimulus, the dependency on caspase-1 for IL-1β secretion is only partial and a higher level of mature IL-1β secretion is observed with longer periods of priming than in hematopoietic macrophages. Prolonged IL-1β secretion from microglia likely occurs as a result of a deficit in negative regulation mechanisms as compared to macrophages. As an additional consideration, activation of the inflammasome in peripheral macrophages serves in a regulatory capacity in the induction of pyroptotic cell death to remove the damaging immune cell. How this translates to microglia remains in question given the long-lived nature of these cells.
Conclusion
The interest in metabolic functions of microglia has evolved from our knowledge of mitochondrial demands and responses of peripheral macrophages in their various effector functions. Recent findings have set the framework for an association between the metabolic status of immune cells with the characteristics of an immune response against pathogens. The majority of studies have relied on different pro-inflammatory stimuli, such as virus, GM-CSF, LPS, LPS + INFγ, or IL-4, to induce cells to examine macrophage metabolism in vitro. However, the resulting phenotype and metabolic profiles can differ with not all stimuli leading towards glycolysis. Conversely, the diverse non-inflammatory stimuli normally examined, i.e., IL-10, glucocorticoids, IL-13, M-CSF, and IL-4, are grouped together[74]; however, similar to the pro-inflammatory stimuli, the phenotypic change may differ. This is not unexpected given that macrophage activation states display multiple profiles depending on the initiating stimuli[206]. However, examination of metabolic adaptations of macrophages has demonstrated that such adaptations are critical factors regulating a variety of immune cell responses. The need to rapidly modulate cellular responses to pathogen or inflammatory signals demands a remodeling of the metabolic pathways to execute such actions. While many of the basic responses translate across peripheral macrophages and microglia, the uniqueness of microglia suggests that this may not be a complete translation across cells. Additionally, the limited range of inducing stimuli examined in microglia cells raises the question of how the cells will compare given a broader range of stimuli. Further exploration of similarities and uniqueness will contribute to our understanding of the interplay between metabolism and immune cell responses as they apply to the nervous system. It may also offer a framework from which to address issues of translation between experimental animal data to human disease conditions that involve the innate immune system[207-209]. Understanding the mitochondrial-related characteristics of microglia will likely be critical in identifying successful therapeutic approaches to the detrimental effects of neuroinflammation or in facilitating repair.
DeclarationsAcknowledgments
The authors acknowledge Drs. Christopher McPherson, Christian Lefebvre d’Hellencourt, and Negin Martin for providing reviewer comments on the manuscript.
Authors’ contributions
Contributed to the conceptualization, design and interpretation of the experiments and in manuscript preparation: Childers G
Generated the original data: Lopez Hernandes I, Giridharan S
Contributed to the conceptualization of the manuscript, data interpretation, and writing of the final manuscript: Harry GJ
Availability of data and materials
Not applicable.
Financial support and sponsorship
The research was supported by NIH intramural research funding ES021164.
Conflicts of interest
All authors declared that there are no conflicts of interest.
KryskoDVAgostinisPKryskoOGargADBachertCEmerging role of damage-associated molecular patterns derived from mitochondria in inflammation.2011321576410.1016/j.it.2011.01.00521334975BoyapatiRKTamborskaADorwardDAHoGTAdvances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases.2017616910.12688/f1000research.10397.128299196PMC5321122ShimadaKCrotherTRKarlinJDagvadorjJChibaNOxidized mitochondrial DNA activated the NRLP3 inflammasome during apoptosis.2012364011410.1016/j.immuni.2012.01.00922342844PMC3312986O’NeillLAJKishtonRJRathmellJA guide to immunometabolism for immunologists.2016165536510.1038/nri.2016.7027396447PMC5001910RussellDGHuangLVanderVenBCImmunometabolism at the interface between macrophages and pathogens.20191929130410.1038/s41577-019-0124-930679807PMC7032560LynchMACan the emerging field of immunometabolism provide insights into neuroinflammation?202018410171910.1016/j.pneurobio.2019.10171931704314GhoshMXuYPearseDDCyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines.201613910.1186/s12974-015-0463-926757726PMC4711034ButovskyOJedrychowskiMPMooreCSCialicRLanserAJIdentification of a unique TGF-beta-dependent molecular and functional signature in microglia.2014171314310.1038/nn.359924316888PMC4066672DurafourtBAMooreCSZammitDAJohnsonTAZaguiaFComparison of polarization properties of human adult microglia and blood-derived macrophages.2012607172710.1002/glia.2229822290798FinsenBOwensTInnate immune responses in central nervous system inflammation.201158538061210.1016/j.febslet.2011.05.03021624366GinhouxFGreterMLeboeufMNandiSSeePFate mapping analysis reveals that adult microglia derive from primitive macrophages.2010330841510.1126/science.119463720966214PMC3719181HickmanSEKingeryNDOhsumiTKBorowskyMLWangLCThe microglial sensome revealed by direct RNA sequencing.201316189690510.1038/nn.355424162652PMC3840123HoltmanIRSkolaDGlassCKTranscriptional control of microglia phenotypes in health and disease.20171273220910.1172/JCI9060428758903PMC5669536RansohoffRMBrownMAInnate immunity in the central nervous system.201212211647110.1172/JCI5864422466658PMC3314450CrottiARansohoffRMMicroglial physiology and pathophysiology: insights from genome-wide transcriptional profiling.2016445051510.1016/j.immuni.2016.02.01326982357BorstKSchwabenlandMPrinzMMicroglia metabolism in health and disease.201913010433110.1016/j.neuint.2018.11.00630423423HawkinsBTDavisTPThe blood-brain barrier/neurovascular unit in health and disease.2005571738510.1124/pr.57.2.415914466HermannDMEl-AliAThe abluminal endothelial membrane in neurovascular remodeling in health and disease.20125re410.1126/scisignal.200288622871611IferganIKébirHBernardMWosikKDodelet-DevillersAThe blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells.20081317859910.1093/brain/awm29518156156MuldoonLLAlvarezJIBegleyDJBoadoRJDel ZoppoGJImmunologic privilege in the central nervous system and the blood-brain barrier.201333132110.1038/jcbfm.2012.15323072749PMC3597357BanerjeeSBhatMANeuron-glial interactions in blood-brain barrier formation.2007302355810.1146/annurev.neuro.30.051606.09434517506642PMC2824917KingILDickendesherTLSegalBMCirculating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease.20091133190710.1182/blood-2008-07-16857519196868PMC2665891MildnerASchmidtHNitscheMMerklerDHanischUKMicroglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions.20071215445310.1038/nn201518026096VallieresLSawchenkoPEBone marrow-derived cells that populate the adult mouse brain preserve their hematopoietic identity.200323519720710.1523/JNEUROSCI.23-12-05197.200312832544PMC6741180TrifiloMJMontalto-MorrisonCStilesLNHurstKRHardisonJLCXC chemokine ligand 10 controls viral infection in the central nervous system: evidence for a role in innate immune response through recruitment and activation of natural killer cells.2003785859410.1128/jvi.78.2.585-594.200414694090PMC368822GonzálezHPachecoRT-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases.20141120110.1186/s12974-014-0201-825441979PMC4258012LiJ1GranBZhangGXVenturaESSiglientiIDifferential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia.20032159510310.1016/s0022-510x(03)00203-x14568135Romero-SuárezSDel RioSerrato ABuenoRJBrunotte-StreckerDStehleCThe central nervous system contains ILC1s that differ from NK cells in the response to inflammation.201910233710.3389/fimmu.2019.0233731649664PMC6795712GinhouxFJungSMonocytes and macrophages: developmental pathways and tissue homeostasis.20141439240410.1038/nri367124854589YamasakiRLuHButovskyOOhnoNRietschAMDifferential roles of microglia and monocytes in the inflamed central nervous system.201421115334910.1084/jem.2013247725002752PMC4113947DavalosDGrutzendlerJYangGKimJVZuoYATP mediates rapid microglial response to local brain injury in vivo.20058752810.1038/nn147215895084NimmerjahnAKirchhoffFHelmchenFResting microglial cells are highly dynamic surveillants of brain parenchyma in vivo.20053081314810.1126/science.111064715831717ChiuIMMorimotoETGoodarziHLiaoJTO’KeeffeSA neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model.2013438540110.1016/j.celrep.2013.06.01823850290PMC4272581AngataTKerrSCGreavesDRVarkiNMCrockerPRCloning and characterization of human Siglec-11. A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia.2002277244667410.1074/jbc.M20283320011986327TakahashiKRochfordCDNeumannHClearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2.20052016475710.1084/jem.2004161115728241PMC2213053KawaiTAkiraSThe role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.2010113738410.1038/ni.186320404851WilkinsonKEl KhouryJMicroglial scavenger receptors and their roles in the pathogenesis of Alzheimer’s disease.2012201248945610.1155/2012/48945622666621PMC3362056PeiZPangHQianLYangSWangTMAC1 mediates LPS-induced production of superoxide by microglia: the role of pattern recognition receptors in dopaminergic neurotoxicity.20075513627310.1002/glia.2054517654704ChenGYNuñezGSterile inflammation: sensing and reacting to damage.2010108263710.1038/nri287321088683PMC3114424ShechterRSchwartzMCNS sterile injury: just another wound healing?2013191354310.1016/j.molmed.2012.11.00723279948McPhersonCAMerrickBAHarryGJIn vivo molecular markers for pro-inflammatory cytokine M1 stage and resident microglia in trimethyltin-induced hippocampal injury.201425455610.1007/s12640-013-9422-324002884PMC3880630KonoHRockKLHow dying cells alert the immune system to danger.200882798910.1038/nri221518340345PMC2763408TakeuchiOAkiraSPattern recognition receptors and inflammation.20101408052010.1016/j.cell.2010.01.02220303872BiberKNeumannHInoueKBoddekeHWNeuronal ‘On’ and ‘Off’ signals control microglia.20073059660210.1016/j.tins.2007.08.00717950926HanischUKKettenmannHMicroglia: active sensor and versatile effector cells in the normal and pathologic brain.20071013879410.1038/nn199717965659RansohoffRMCardonaAEThe myeloid cells of the central nervous system parenchyma.20104682536210.1038/nature0961521068834KettenmannHHanischUKNodaMVerkhratskyAPhysiology of microglia.20119146155310.1152/physrev.00011.201021527731DomercqMVázquez-VilloldoNMatuteCNeurotransmitter signaling in the pathophysiology of microglia.201374910.3389/fncel.2013.0004923626522PMC3630369KierdorfKPrinzMFactors regulating microglia activation.201374410.3389/fncel.2013.0004423630462PMC3632747PocockJMKettenmannHNeurotransmitter receptors on microglia.2007305273510.1016/j.tins.2007.07.00717904651Garcia-RevillaJAlonso-BellidoIMBurguillosMAHerreraAJEspinosa-OlivaAMReformulating pro-oxidant microglia in neurodegeneration.20198171910.3390/jcm810171931627485PMC6832973LeeJKChungJKannarkatGTTanseyMGCritical role of regulator G-protein signaling 10 (RGS10) in modulating macrophage M1/M2 activation.20138e8178510.1371/journal.pone.008178524278459PMC3836764SeifertSPannellMUckertWFärberKKettenmannHTransmitter- and hormone-activated Ca(2+) responses in adult microglia/brain macrophages in situ recorded after viral transduction of a recombinant Ca(2+) sensor.2011493657510.1016/j.ceca.2011.03.00521536328AjamiBSamusikNWieghoferPHoPPCrottiASingle-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models.2018215415110.1038/s41593-018-0100-x29507414PettersenJSFuentes-DuculanJSuárez-FariñasMPiersonKCPitts-KieferATumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated.201113113223010.103/jid.2011.921307877PMC3334331Ziegler-HeitbrockLHoferTPJToward a refined definition of monocyte subsets.201342310.3389/fimmu.2013.0002323382732PMC3562996MosserDMEdwardsJPExploring the full spectrum of macrophage activation.200889586910.1038/nri244819029990PMC2724991GordonSAlternative activation of macrophages.20033233510.1038/nri97812511873LynchMAThe multifaceted profile of activated microglia.2009401395610.1007/s12035-009-8077-919629762BiswasSKMantovaniAMacrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.2010118899610.1038/ni.193720856220SicaAMantovaniAMacrophage plasticity and polarization: in vivo veritas.20121227879510.1172/JCI5964322378047PMC3287223HumeDAFreemanTCTranscriptomic analysis of mononuclear phagocyte differentiation and activation.2014262748410.1111/imr.1221125319328ColtonCAHeterogeneity of microglial activation in the innate immune response in the brain.2009439941810.1007/s11481-009-9164-419655259PMC2773116MichelucciAHeurtauxTGrandbarbeLMorgaEHeuschlingPCharacterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-beta.200921031210.1016/j.jneuroim.2009.02.00319269040BocheDPerryVHNicollJAReview: activation patterns of microglia and their identification in the human brain.20133931810.1111/nan.1201123252647CherryJDOlschowkaJAO’BanionMKNeuroinflammation and M2 microglia: the good, the bad, and the inflamed.2014119810.1186/1742-2094-11-9824889886PMC4060849MurrayPJAllenJEBiswasSKFisherEAGilroyDWMacrophage activation and polarization: nomenclature and experimental guidelines.201441142010.1016/j.immuni.2014.06.00825035950PMC4123412LoaneDKumarAMicroglia in the TBI Brain: the good, the bad, And the dysregulated.20162753162710.1016/j.expneurol.2015.08.01826342753PMC4689601OrihuelaRMcPhersonCAHarryGJMicroglial M1/M2 polarization and metabolic states20161736496510.1111/bph.1313925800044PMC4742299GerrickKYGerrickERGuptaAWheelanSJYegnasubramanianSTranscriptional profiling identifies novel regulators of macrophage polarization.201813e020860210.1371/journal.pone.020860230532146PMC6286176RansohoffRMA polarizing question: do M1 and M2 microglia exist?2016199879110.1038/nn.433827459405SteinMInterleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation.19921762879210.1084/jem.176.1.2871613462PMC2119288DoyleAGHerbeinGMontanerLJMintyAJCaputDInterleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma.1994241441510.1002/eji.18302406307911424MartinezFOGordonSThe M1 and M2 paradigm of macrophage activation: time for reassessment.2014611310.12703/P6-1324669294PMC3944738MillsELO’NeillLAReprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal.201646132110.1002/eji.20144542726643360MurrayPJUnderstanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response.200663798610.1016/j.coph.2006.01.01016713356BordtEAPolsterBMNADPH oxidase- and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: a bipartisan affair?201476344610.1016/j.freeradbiomed.2014.07.03325091898PMC4252610DashtyMA quick look at biochemistry: carbohydrate metabolism.20134613395210.1016/j.clinbiochem.2013.04.02723680095Liemburg-ApersDCSchirrisTJRusselFGWillemsPHKoopmanWJMitoenergetic dysfunction triggers a rapid compensatory increase in steady-state glucose flux.201510913728610.1016/j.bpj.2015.08.00226445438PMC4601044VazquezALiuJZhouYOltvaiZNCatabolic efficiency of aerobic glycolysis: the Warburg effect revisited.201045810.1186/1752-0509-4-5820459610PMC2880972WarburgOOn respiratory impairment in cancer cells.19561242697013351639Vander HeidenMGCantleyLCThompsonCBUnderstanding the Warburg effect: the metabolic requirements of cell proliferation.200932410293310.1126/science.116080919460998PMC2849637WeinbergSESenaLAChandelNSMitochondria in the regulation of innate and adaptive immunity.2015424061710.1016/j.immuni.2015.02.00225786173PMC4365295KellyBO’NeillLAMetabolic reprogramming in macrophages and dendritic cells in innate immunity.2015257718410.1038/cr.2015.6826045163PMC4493277MehtaMMWeinbergSEChandelNSMitochondrial control of immunity: beyond ATP.2017176082010.1038/nri.2017.6628669986ViolaAMunariFSanchez-RodriguezRScolaroTCastegnaAThe metabolic signature of macrophage responses.201910146210.3389/fimmu.2019.0146231333642PMC6618143ZuoHWanYMetabolic reprogramming in mitochondria of myeloid cells.20209510.3390/cells901000531861356PMC7017304BiswasSKMantovaniAOrchestration of metabolism by macrophages.201215432710.1016/j.cmet.2011.11.01322482726RyanDGO’NeillLAJKrebs cycle reborn in macrophage immunometabolism.2020Epub ahead of print. doi: 10.1146/annurev-immunol-081619-10485031986069BernhartEKollroserMRechbergerGReicherHHeinemannALysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture.2010101415810.1002/pmic.20090019519899077PMC4060044MossDWBatesTEActivation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function.2001135293810.1046/j.1460-9568.2001.01418.x11168560ZuoHWanYMetabolic reprogramming in mitochondria of myeloid cells.20209510.3390/cells901000531861356PMC7017304LartigueLFaustinBMitochondria: Metabolic regulators of innate immune responses to pathogens and cell stress.20134520525610.1016/j.biocel.2013.06.01423838171VolobouevaLAEmeryJFSunXGiffardRGInflammatory response of microglial BV-2 cells includes a glycolytic shift and is modulated by mitochondrial glucose-regulated protein 75/mortalin.20135877566210.1016/j.febslet.2013.01.06723395614PMC3603371Gimeno-BayonJLopez-LopezARodriguezMJMahyNGlucose pathways adaptation supports acquisition of activated microglia phenotype.2014927233110.1002/jnr.2335624510633ChenaisBMorjaniHDrapierJCImpact of endogenous nitric oxide on microglial cell energy metabolism and labile iron pool.2002816152310.1046/j.1471-4159.2002.00864.x12065670PMC2816204Rodríguez-PradosJCTravésPGCuencaJRicoDAragonesJSubstrate fate in activated macrophages: a comparison between innate, classic, and alternative activation.20101856051410.4049/jimmunol.090169820498354OdegaardJIChawlaAAlternative macrophage activation and metabolism.201162759710.1146/annurev-pathol-011110-13013821034223PMC3381938MantovaniABiswasSKGaldieroMRSicaALocatiMMacrophage plasticity and polarization in tissue repair and remodelling.20132291768510.1002/path.413323096265Galvan-PenaSO’NeillLAMetabolic reprograming in macrophage polarization.2014542010.3389/fimmu.2014.0042025228902PMC4151090MillsELKellyBO’NeillLAJMitochondria are the powerhouses of immunity.2017184889810.1038/ni.370428418387NewsholmePCuriRGordonSNewsholmeEAMetabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages.1986239121510.1042/bj23901213800971PMC1147248NewsholmePGordonSNewsholmeEARates of utilization and fates of glucose, glutamine, pyruvate, fatty acids and ketone bodies by mouse macrophages.1987242631610.1042/bj24206313593269PMC1147758HaschemiAKosmaPGilleLEvansCRBurantCFThe sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism.2012158132610.1016/j.cmet.2012.04.02322682222PMC3370649BlagihJJonesRGPolarizing macrophages through reprogramming of glucose metabolism.201215793510.1016/j.cmet.2012.05.00822682218BonoraMPatergnaniSRimessiADe MarchiESuskiJMATP synthesis and storage.201283435710.1007/s11302-012-9305-822528680PMC3360099BernierLPBohlenCJYorkEMChoiHBKamyabiANanoscale surveillance of the brain by microglia via cAMP-regulated filopodia.201927289590810.1016/j.celrep.2019.05.01031167136MadryCKyrargyriVArancibia-CarcamoILJolivetRKohsakaSMicroglial ramification, surveillance, and interleukin-1beta release are regulated by the two-pore domain K(+) channel THIK-1.20189729931210.1016/j.neuron.2017.12.00229290552PMC5783715GhoshSCastilloEFriasESSwansonRABioenergetic regulation of microglia.20186612001210.1002/glia.2327129219210PMC5903989CherryJDOlschowkaJAO’BanionMKAre ‘resting’ microglia more ‘m2’?2014559410.3389/fimmu.2014.0059425477883PMC4235363BaikSHKangSLeeWChoiHChungSA breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer’s disease.201930493507.e610.1016/j.cmet.2019.06.00531257151HollandRMcIntoshALFinucaneOMMelaVRubio-AraizAInflammatory microglia are glycolytic and iron retentive and typify the microglia in APP/PS1 mice.2017681839610.1016/j.bbi.2017.10.01729061364McIntoshAMelaVHartyCMinogueAMCostelloDAIron accumulation in microglia triggers a cascade of events that leads to altered metabolism and compromised function in APP/PS1 mice.2019296062110.1111/bpa.1270430661261WangTLiuHLianGZhangSYWangXHIF1 α -induced glycolysis metabolism is essential to the activation of inflammatory macrophages.2017201711010.1155/2017/902932729386753PMC5745720NairSSobotkaKSJoshiPGressensPFleissBLipopolysaccharide-induced alteration of mitochondrial morphology induces a metabolic shift in microglia modulating the inflammatory response in vitro and in vivo.20196710476110.1002/glia.2358730637805ChénaisBMorjaniHDrapierJCImpact of endogenous nitric oxide on microglial cell energy metabolism and labile iron pool.2002816152310.1046/j.1471-4159.2002.00864.x12065670PMC2816204BanatiRBEgenspergerRMaassenAHagerGKreutzbergGWMitochondria in activated microglia in vitro.2004335354110.1007/s11068-004-0515-715906160FergerAICampanelliLReimerVMuthKNMerdianIEffects of mitochondrial dysfunction on the immunological properties of microglia201074510.1186/1742-2094-7-4520701773PMC2925359FinucaneOMSugrueJRubio-AraizAGuillot-SestierMVLynchMAThe NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1beta dependent manner in macrophages.20199403410.1038/s41598-019-40619-130858427PMC6411754IpWKEHoshiNShouvalDSSnapperSMedzhitovRAnti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages.2017356513910.1126/science.aal353528473584PMC6260791MurrayPJWynnTAObstacles and opportunities for understanding macrophage polarization.2011895576310.1189/jlb.071040921248152PMC3058818BiswasSKChittezhathMShalovaINLimJYMacrophage polarization and plasticity in health and disease.201253112410.1007/s12026-012-8291-922418728HuangSCEvertsBIvanovaYO’SullivanDNascimentoMCell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages.2014158465510.1038/ni.295625086775PMC4139419LiuPSWangHLiXChaoTTeavTAlpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming.2017189859410.1038/ni.379628714978VatsDMukundanLOdegaardJIZhangLSmithKLOxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation.20064132410.1016/j.cmet.2006.05.01116814729PMC1904486MillsCDKincaidKAltJMHellmanMJHillAMM-1/M-2 macrophages and the Th1/Th2 paradigm.200016461667310.4049/jimmunol.164.12.616610843666De SimoneRAjmone-CatMAPandolfiMBernardoADe NuccioCThe mitochondrial uncoupling protein-2 is a master regulator of both M1 and M2 microglial responses.20151351475610.1111/jnc.1324426173855WestAPBrodskyIERahnerCWooDKErdjument-BromageHTLR signalling augments macrophage bactericidal activity through mitochondrial ROS.20114724768010.1038/nature0997321525932PMC3460538Van den BosscheJBaardmanJOttoNAvan der VeldenSNeeleAEMitochondrial dysfunction prevents repolarization of inflammatory macrophages.2016176849610.1016/j.celrep.2016.09.00827732846PoderosoJJHelfenbergerKPoderosoCThe effect of nitric oxide on mitochondrial respiration.201988617210.1016/j.niox.2019.04.00530999001HuYMaiWChenLCaoKZhangBmTOR-mediated metabolic reprogramming shapes distinct microglia functions in response to lipopolysaccharide and ATP.20206810314510.1002/glia.2376031793691LiDWangCYaoYChenLLiuGmTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type.20163033889910.1096/fj.201600495R27342766UllandTKSongWMHuangSCUlrichJDSergushichevATREM2 maintains microglial metabolic fitness in alzheimer’s disease.201717064963.e1310.1016/j.cell.2017.07.02328802038PMC5573224ZhaoXLiaoYMorganSMathurRFeustelPNoninflammatory changes of microglia are sufficient to cause epilepsy.20182220809310.1016/j.celrep.2018.02.00429466735PMC5880308BedardKKrauseKHThe NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.20078724531310.1152/physrev.00044.200517237347PawateSShenQFanFBhatNRRedox regulation of glial inflammatory response to lipopolysaccharide and interferon gamma.2004775405110.1002/jnr.2018015264224QinLLiuYWangTWeiSJBlockMLNADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia.200427914152110.1074/jbc.M30765720014578353LoaneDJStoicaBAPajoohesh-GanjiAByrnesKRFadenAIActivation of metabotropic glutamate receptor 5 modulates microglial reactivity and neurotoxicity by inhibiting NADPH oxidase.2009284156293910.1074/jbc.M80613920019364772PMC2708859ChoiSHAidSKimHWJacksonSHBosettiFInhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation.201212029230110.1111/j.1471-4159.2011.07572.x22050439PMC3386526EguchiHFujiwaraNSakiyamaHYoshiharaDSuzukiKHydrogen peroxide enhances LPS-induced nitric oxide production via the expression of interferon beta in BV-2 microglial cells.2011494293310.1016/j.neulet.2011.02.04721354265ManderPKJekabsoneABrownGCMicroglia proliferation is regulated by hydrogen peroxide from NADPH oxidase.200617610465210.4049/jimmunol.176.2.104616393992RoyAJanaAYatishKFreidtMBFungYKReactive oxygen species up-regulate CD11b in microglia via nitric oxide: implications for neurodegenerative diseases.2008456869910.1016/j.freeradbiomed.2008.05.02618590811PMC2701551TaetzschTLevesqueSMcGrawCBrookinsSLuqaRRedox Regulation of NF-κB p50 and M1 Polarization in Microglia.2015634234010.1002/glia.2276225331559PMC4322433YuanYHSunJDWuMMHuJFPengSYRotenone could activate microglia through NF-kB associated pathway.20133815536010.1007/s11064-013-1055-723645222KletzienRFHarrisPKFoellmiLAGlucose-6-phosphate dehydrogenase: a “housekeeping” enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress.199481748110.1096/fasebj.8.2.81194888119488SalveminiFFranzéAIervolinoAFilosaSSalzanoSEnhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression.19992742750710.1074/jbc.274.5.27509915806MustacichDPowisGThioredoxin reductase.20003461810657232PMC1220815YingWNAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences.20081017920610.1089/ars.2007.167218020963ShenYKapfhamerDMinnellaAMKimJEWonSJBioenergetic state regulates innate inflammatory responses through the transcriptional co-repressor CtBP.2017862410.1038/s41467-017-00707-028935892PMC5608947WangLPavoluSDuXBhuckoryMXuHGlucose transporter 1 critically controls microglial activation through facilitating glycolysis.201914210.1186/s13024-019-0305-930634998PMC6329071KalsbeekMJMulderLYiCXMicroglia energy metabolism in metabolic disorder.2016438273510.1016/j.mce.2016.09.02827687525PayneJMaherFSimpsonIMatticeLDaviesPGlucose transporter Glut 5 expression in microglial cells.1997213273110.1002/(sici)1098-1136(199711)21:3<327::aid-glia7>3.0.co;2-19383041HsiehCLiuCLeeCYuLEWangJYAcute glucose fluctuation impacts microglial activity, leading to inflammatory activation or self-degradation.2019984010.1038/s41598-018-37215-030696869PMC6351546ChenJSunZJinMTuYWangSInhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-κB pathway.20173051081410.1016/j.jneuroim.2017.02.01028284330TannahillGMCurtisAMAdamikJPalsson-McDermottEMMcGettrickAFSuccinate is an inflammatory signal that induces IL-1β through HIF-1α.20134962384210.1038/nature1198623535595PMC4031686O’NeillLAJPearceEJImmunometabolism governs dendritic cell and macrophage function.2016213152310.1084/jem.2015157026694970PMC4710204WangFZhangSJeonRVuckovicJiangXInterferon gamma induces reversible metabolic reprogramming of M1 macrophages to sustain cell viability and pro-inflammatory activity.2018303031610.1016/j.ebiom.2018.02.00929463472PMC5953001ChoiSJShinIJJeKHMinEKKimEJHypoxia antagonizes glucose deprivation on interleukin 6 expression in an Akt dependent, but HIF-1/2α independent manner.20138e5866210.1371/journal.pone.005866223520526PMC3592797ChurchwardMATchirDRToddKGMicroglial function during glucose deprivation: inflammatory and neuropsychiatric implications.20185514778710.1007/s12035-017-0422-928176274PMC5820372WengFZhangSVuckovicIRyounghoonJLermanAGlycolytic stimulation is not a requirement for M2 macrophage differentiation.2018284637510.1016/j.cmet.2018.08.01230184486PMC6449248VenterGOerlemansFTJJWijersMWillemseMFransenJAMGlucose controls morphodynamics of LPS-stimulated macrophages.20149e9678610.1371/journal.pone.009678624796786PMC4010488MeiserJKrämerLSapcariuSCBattelloNGhelfiJPro-inflammatory macrophages sustain pyruvate oxidation through pyruvate dehydrogenase for the synthesis of itaconate and to enable cytokine expression.201629139324610.1074/jbc.M115.67681726679997PMC4759172ShayJECeleste-SimonMHypoxia-inducible factors: crosstalk between inflammation and metabolism.2012233899410.1016/j.semcdb.2012.04.00422525300LiuPSWangHLiXChaoTTeavTα-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming.201789859410.1038/ni.379628714978MoonJSHisataSParkMADeNicolaGMRyterSWmTORC1-induced HK1-dependent glycolysis regulates NLRP3 inflammasome activation.2015121021510.1016/j.celrep.2015.05.04626119735PMC4858438XieMYuYKangRZhuSYangLPKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation.201671328010.1038/ncomms1328027779186PMC5093342WenHMiaoEATingJPMechanisms of NOD-like receptor-associated inflammasome activation.2013394324110.1016/j.immuni.2013.08.03724054327PMC3835203AdamczakSEde RiveroVaccari JPDaleGBrandFJNonnerDPyroptotic neuronal cell death mediated by the AIM2 inflammasome.2014346212910.1038/jcbfm.2013.23624398937PMC3982080KaushalVDyeRPakavathkumarPNeuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation.20152216768610.1038/cdd.2015.1625744023PMC4563782YogarajahTOngKCPereraDWongKTAIM2 inflammasome-mediated pyroptosis in enterovirus A71-infected neuronal cells restricts viral replication.20177584510.1038/s41598-017-05589-228724943PMC5517550MinkiewiczJde RiveroVaccari JPKeaneRWHuman astrocytes express a novel NLRP2 inflammasome.20138736556710.1002/glia.22499FreemanLGuoHDavidCNBrickeyWJJhaSNLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes.201721413517010.1084/jem.2015023728404595PMC5413320de RiveroVaccari JPDietrichWDKeaneRWActivation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury.2014343697510.1038/jcbfm.2013.22724398940PMC3948131BurmSMZuiderwijk-SickEA‘t JongAEvan der PuttenCVethJInflammasome-induced IL-1β secretion in microglia is characterized by delayed kinetics and is only partially dependent on inflammatory caspases.2015356788710.1523/JNEUROSCI.2510-14.201525589762PMC6605364HornungVBauernfeindFHalleASamstadEOKonoHSilica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.200898475610.1038/ni.163118604214PMC2834784FranchiLEigenbrodTMuñoz-PlanilloRNuñezGThe inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis.200910241710.1038/ni.170319221555PMC2820724HanamsagarRTorresWKielianTInflammasome activation and IL-1beta/IL-18 processing are influenced by distinct pathways in microglia.20111197364810.1111/j.1471-4159.2011.07481.x21913925PMC3202981LunovOSyrovetsTLoosCNienhausGUMailanderVAmino-Functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages.2011596485710.1021/nn203596e22111911SchnaarsMBeckertHHalleAAssessing β-amyloid-induced NLRP3 inflammasome activation in primary microglia.201310401810.1007/978-1-62703-523-1_123852592HughesMMO’NeillLAJMetabolic regulation of NLRP3.2018281889810.1111/imr.1260829247992HeidMEKeyelPAKamgaCShivaSWatkinsSCMitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation.20131915230810.4049/jimmunol.130149024089192PMC3833073GustinAKirchmeyerMKoncinaEFeltenPLosciutoSNLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes.20151910:e013062410.1371/journal.pone.013062426091541PMC4474809AfoninaISZhongZKarinMBeyaertRLimiting inflammation - the negative regulation of NF-kB and the NLRP3 inflammasome.201718861910.1038/ni.377228722711ElliottEISutterwalaFSInitiation and perpetuation of NLRP3 inflammasome activation and assembly.2015265355210.1111/imr.1228625879282PMC4400874BrozPDixitVMInflammasomes: mechanism of assembly, regulation and signalling.2016164072010.1038/nri.2016.5827291964ZambettiLPLaudisiFLicandroGRicciardi-CastagnoliPMortellaroAThe rhapsody of NLRPs: master players of inflammation...and a lot more.201253789010.1007/s12026-012-8272-z22427013DinarelloCAImmunological and inflammatory functions of the interleukin-1 family.2009275195010.1146/annurev.immunol.021908.13261219302047EvavoldCLRuanJTanYXiaSWuHThe pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages.2018483544.e610.1016/j.immuni.2017.11.01329195811PMC5773350HeiligRDickMSSborgiLMeunierEHillerSThe Gasdermin-D pore acts as a conduit for IL-1β secretion in mice.2018485849210.1002/eji.20174740429274245LeeHMKangJLeeSJJoEKMicroglial activation of the NLRP3 inflammasome by the priming signals derived from macrophages infected with mycobacteria.2013614415210.1002/glia.2244823280493ViganòEMortellaroACaspase-11: the driving factor for noncanonical inflammasomes.2013432240510.1002/eji.20134380024037676FranklinBSBossallerLDe NardoDRatterJMStutzAThe adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation.2014157273710.1038/ni.291324952505PMC4116676VenegasCKumarSFranklinBSDierkesTBrinkschulteRMicroglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease.20175523556110.1038/nature2515829293211GurungPLukensJRKannegantiTDMitochondria: diversity in the regulation of NLRP3 inflammasome.2015319320110.1016/j.molmed.2014.11.00825500014PMC4352396ShimadaKCrotherTRKarlinJDagvadorjJChibaNOxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis.2012364011410.1016/j.immuni.2012.01.00922342844PMC3312986NakahiraKHaspelJARathinamVALeeSJDolinayTAutophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome.2011122223010.1038/ni.198021151103PMC3079381ZhongZLiangSSanchez-LopezEHeFShalapourSNew mitochondrial DNA synthesis enables NLRP3 inflammasome activation.201856019820310.1038/s41586-018-0372-z30046112PMC6329306ZhouRYazdiASMenuPTschoppJA role for mitochondria in NLRP3 inflammasome activation.2011469221510.1038/nature0966321124315BauernfeindFBartokERiegerAFranchiLNúñezGCutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome.2011187613710.4049/jimmunol.110061321677136PMC3131480ElliottEIMillerABanothBIyerSSStotlandACutting edge: mitochondrial assembly of the NLRP3 inflammasome complex is initiated at priming.201820030475210.4049/jimmunol.170172329602772PMC5916517CodoloGPlotegherNPozzobonTBrucaleMTessariITriggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies.20138e5537510.1371/journal.pone.005537523383169PMC3561263ParajuliBSonobeYHoriuchiHTakeuchiHMizunoTOligomeric amyloid beta induces IL-1beta processing via production of ROS: implication in Alzheimer’s disease.20134e97510.1038/cddis.2013.50324357806PMC3877570BellezzaIGrottelliSCostanziEScarpelliPPignaEPeroxynitrite activates the NLRP3 inflammasome cascade in SOD1(G93A) mouse model of amyotrophic lateral sclerosis.20185523506110.1007/s12035-017-0502-x28357805VenegasCHenekaMTInflammasome-mediated innate immunity in Alzheimer’s disease.201933130758410.1096/fj.20190043931702392DeoraVLeeJDAlbornozEAMcAlaryLJagarajCJThe microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins.2020684072110.1002/glia.2372831596526XueJSchmidtSVSanderJDraffehnAKrebsWTranscriptome-based network analysis reveals a spectrum model of human macrophage activation.2014402748810.1016/j.immuni.2014.01.00624530056PMC3991396HealyLMYaqubiMLudwinSAntelJPSpecies differences in immune-mediated CNS tissue injury and repair: a (neuro)inflammatory topic.2020688112910.1002/glia.2374631724770StogerJLGijbelsMJvan der VeldenSMancaMvan der LoosCMDistribution of macrophage polarization markers in human atherosclerosis.2012225461810.1016/j.atherosclerosis.2012.09.01323078881Van den BosscheJO’NeillLAMenonDMacrophage immunometabolism: where are we (going)?20173839540610.1016/j.it.2017.03.00128396078